People living with HIV (PLWH) are affected by a higher incidence skin disorders, which are often associated with high morbidity and mortality. In particular, psoriasis affects PLWH severely and 
. Moreover, HIV-positive patients are commonly affected by skin disorders, which are often associated with high morbidity and mortality (Amerio et al., 2013; Khambaty & Hsu, 2010 ).
In particular, though its prevalence is not the highest among the skin disorders, psoriasis affects PLWH severely and for a longer time than the general population (Menon et al., 2010) .
HIV-associated psoriasis can be observed in every stage of the HIV infection, but its onset seems to be related to risk factors such as a low CD4+ T-cell count and a known familiarity for the disease (Fernandes, Pinto, & Cardoso, 2011) . The fact that more than a type of psoriasis can be observed at the same time in the same patient can make it harder to diagnose the problem (Castillo, Racaza, & Roa, 2014; Menon et al., 2010) . Moreover, HIV-associated psoriasis shows a progressive course and it is particularly resistant to traditional treatments (Cepeda, Williams, Ishimori, Weisman, & Reveille, 2008) . Traditional psoriasis treatments consist in immunosuppressive drugs, such as cyclosporine A and methotrexate, which are not easily viable in this subset of patients (Cepeda et al., 2008) . Therefore, a careful diagnostic process to determine HIV-associated psoriasis' severity and to choose the right treatment in relation to the patient's immunologic status is of the utmost importance.
The aim of this review is to identify key data and risk factors about psoriasis epidemiology and its treatment in HIV positive people.
| EPIDEMIOLOGY
Psoriasis is a very common inflammatory skin disease. In Western countries, it is estimated to affect 2-4% of the population, with a prevalence that in adults varies from the 0.91% reported in the United States to the 8.5% reported in Norway (Parisi, Symmons, Griffiths, Ashcroft, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, 2013). As for the prevalence, United States claim the lowest incidence (78.9/100.000 people/year), while Italy has the highest (230/100.000 people/year; Parisi et al., 2013) . According to data, psoriasis prevalence varies with age, gender, and geographic regions: it increases with the distance from the equator (Parisi et al., 2013) . Prevalence of psoriasis and psoriatic arthritis seems to be higher in PLWH than in the general population (Borgia et al., 2018; Castillo et al., 2014; Morar, Willis-Owen, Maurer, & Bunker, 2010; Yen et al., 2017) . Psoriasis onset in PLWH used to be associated with a poor prognosis, with a mean life-expectancy varying from 4 to 24 months when not treated (Morar et al., 2010) .
On the other hand, the introduction of the highly active antiretroviral therapy or combined antiretroviral therapy (cART) dramatically changed the natural course of both HIV and psoriasis in PLWH, leading to an improvement of quality and duration of life Facciolà et al., 2017; Guarneri et al., 2016; Nunnari et al., 2012; Pinzone et al., 2015) . Therefore, it is necessary to find newer and safer therapies to treat PLWH affected by psoriasis.
| PATHOGENESIS
Psoriasis is a systemic immune-mediated life-long chronic inflammatory skin disease which, for a long time, was believed to be an organspecific autoimmune disease (Morar et al., 2010; Parker, 2014) . It is characterized by an unbalance in T cell activation, cytokines production, inflammation, and keratinocytes proliferation occurring in genetically predisposed individuals, bearers of the HLA-Cw*0602 allele (Mallon et al., 2013; Morar et al., 2010; Parker, 2014) . On the other hand, it has been demonstrated that genetic predisposition is not sufficient to develop psoriasis. Therefore, environmental factors, such as smoking, alcohol use, obesity, metabolic syndrome, and infectious diseases are to be accounted for triggering the onset or worsening psoriasis (Cedeno-Laurent et al., 2011; Fife, Waller, Jeffes, & Koo, 2007; Ouedraogo & Meyer, 2012) .
It is thought that the main driver of a psoriatic episode is the activation of a CD4 + T helper 1 (Th1) pattern, with the secretion of interleukin (IL)-23, IL-12, interferon (IFN) γ, and tumor necrosis factor (TNF) α (Morar et al., 2010) . CD8+ T cells also, and especially the memory subset of CD8+ T cells, have a central role in the development of skin lesions in psoriasis (Austin, Ozawa, Kikuchi, Walters, & Krueger, 1999; Morar et al., 2010; Parker, 2014) . As a matter of fact, a number of studies demonstrated their presence within epidermis and dermis of the lesions, where they enhance the damage producing proinflammatory cytokines, such as IL-17, IL-22, IFNγ, and TNFα, which further trigger keratinocyte proliferation (Austin et al., 1999; Morar et al., 2010; Parker, 2014) . Moreover, HIV could have a direct role in the onset or exacerbation of psoriasis. As a matter of fact, several studies demonstrated that HIV nef protein operate as superantigen, while HIV tat protein directly stimulate epidermal and endothelial proliferation (Compton, Kupper, & Nadire, 1996; Mahoney et al., 1991; Morar et al., 2010) . 
| CLINICAL FEATURES
Psoriasis is a frequent reason for a dermatologist consultation. Its onset in otherwise healthy individuals should raise suspicion of a HIV infection when particular aspects, such as multiple subtypes, and risk factors are present (Fernandes et al., 2011; Khambaty & Hsu, 2010) .
As a matter of fact, cutaneous manifestations may onset for the first time or exacerbate when the CD4+ T-cell number severely decreases with the HIV infection progression (Morar et al., 2010) . Especially, it has been observed that the psoriasis severity is inversely related to a low CD4+ T-cell count (Fife et al., 2007) . However, there have been reports of disappearance of the psoriatic skin lesions immediately before death in people with AIDS (Duvic et al., 1987) .
Several studies highlighted how psoriasis characteristics in PLWH are different than general population, and that the severity of the presentation and the frequency of psoriasis is often related to the degree of immune suppression. Moreover, in PLWH more than one of the subtypes described below can be present at the same time (Castillo et al., 2014; Fernandes et al., 2011; Khambaty & Hsu, 2010; Menon et al., 2010; Morar et al., 2010; Parker, 2014) .
Plaque psoriasis is the most common form in general population, it appears with symmetrical erythematous patches or plaques covered with silvery scales. It is itchy and painful, and it can be localized on every surface of the body, even if it preferably affects the face, the scalp, elbows and knees, and skinfolds (Fabbri, Gelmetti, & Leigheb, 2014; Morar et al., 2010) .
Nail psoriasis is characterized by coarse pitting, abnormal nail growth and discoloration (oil-drop lesion), onycholysis, subungual hyperkeratosis, splinter haemorrages, and frank onychodystrophy which, in severe cases, may cause the nail to crumble (Fabbri et al., 2014; Morar et al., 2010) .
Guttate psoriasis primarily affects young adults and children and it is usually triggered by bacterial infection. Its name is due to the small, water-drop-shaped, scaling lesions appearing on the trunk, arms, legs, and scalp (Fabbri et al., 2014) .
Inverse psoriasis (or sebopsoriasis) is the most frequent subtype in PLWH, often triggered by yeasts. It is characterized by greasy scales with exudative crusts mainly affecting the skin in the armpits, in the groin, under the breasts, and around the genitals. Severe cases can also affect seborrheic areas on the scalp, retroauricular, perinasal, and flexural areas (Fabbri et al., 2014; Morar et al., 2010) .
Pustular psoriasis is an uncommon form of the disease during which pus-filled blisters appear on hyperemic and tender skin. When generalized, pustular psoriasis can also cause systemic symptoms such as fever, chills, severe itching, and diarrhea (Fabbri et al., 2014) .
Erythrodermic psoriasis is the least common type of psoriasis, and it is characterized by desquamate large scales which can simulate either lamellar ichthyosis or a chronic erythrodermic drug eruption. It can itch or burn intensely (Fabbri et al., 2014; Morar et al., 1999 Morar et al., , 2010 .
Rupioid psoriasis is an infrequent subtype during which limpet-like, cone-shaped, hyperkeratotic plaques covered with an exudative crust can be observed all over the limbs (Morar et al., 2010) .
Psoriatic arthritis can affect any joint, causing swelling and pain and sometimes it can be the only manifestation of the disease. It could lead to permanent damage (Fabbri et al., 2014) . PLWH are affected by a high prevalence of arthritis, and especially of reactive arthritis.
All clinical subtypes of psoriasis may occur in PLWH, even though guttate psoriasis, inverse psoriasis, and erythrodermic psoriasis are the most commonly found (Menon et al., 2010) . Psoriasis exacerbation has also been described as a part of the immune reconstitution inflammatory syndrome in severely immunocompromised HIV patients beginning cART (Tripathi, Leslie, Maurer, & Amerson, 2015) .
| MANAGEMENT AND TREATMENT
Treatment of psoriasis in PLWH can offer a challenge to the clinician, because of the impaired immunological status of the patient.
For a long time, there have been limited therapeutic choices for PLWH affected by psoriasis. cART, associated with topical preparations, such as calcipotriene, corticosteroids, and tazarotene, still represents first line therapy for mild to moderate psoriasis, and it has even been reported that some cases could benefit by cART alone (Chiricozzi et al., 2012; Fink, Hedley, & Miller, 2017; Khambaty & Hsu, 2010; Menon et al., 2010 
| Phototherapy
Phototherapy is useful in reducing the levels of inflammatory mediators, inactive pruritogenic substances, and histamine. Moreover, it causes a reduction of the keratinocyte proliferation rate (Seckin, Demircay, & Akin, 2007) .
Despite the fact that in vitro has been observed that UV radiations can upregulate HIV transcription, phototherapy use is considered safe and effective in PLWH, not further increasing the risk of melanoma and non-melanoma skin cancers in these patients (BreuerMcHam et al., 1999) .
| Oral retinoids
Oral retinoids, such as acitretin, have been and still are an important option in second line psoriasis treatment of PLWH, alone or associated to phototherapy (Aboulafia, Bundow, Wilske, & Ocas, 2000; Fernandes et al., 2011) .
However, their use is often related to the appearance of adverse effects in PLWH, such as hypertriglyceridemia and pancreatitis, when accompanied to some antiretroviral drugs (Aboulafia et al., 2000) .
Retinoid-related hypertriglyceridemia can also result in an increase of cardiovascular risk, leading to arterial stiffness and even myocardial infarction (Dattilo et al., 2017) .
Moreover, oral retinoids are not effective on psoriatic arthritis (Aboulafia et al., 2000; Castillo et al., 2014; Fernandes et al., 2011) .
| Methotrexate
Methotrexate is the most used immunosuppressant for psoriasis treatment in general population. It is a competitive inhibitor of the dihydrofolate reductase. However, Carrascosa et al. (2016) highlighted in their recommendation that current evidences are not enough to safely introduce this drug in the clinical practice for PLWH. On the other hand, they also report that there are also not evidences for an increased risk in PLWH, leaving the choice and autonomy of use to the clinician (Carrascosa et al., 2016) . As a matter of fact, in early cases of HIV-associated psoriasis, methotrexate administration was reported to be related with a higher incidence of opportunistic infections and progression of the disease (Duvic et al., 1987) . However, later reports demonstrated that its use, in association with TNFα inhibitors, is safe and effective in PLWH, especially in low doses and with a prophylaxis for opportunistic infections (Menon et al., 2010) .
| Cyclosporine
Cyclosporine is a calcineurin inhibitor, which impairs the activation of CD4+ T-lymphocytes. This drug has been successfully used in PLWH, especially in erythrodermic and generalized pustular variants, although it seems to be ineffective in HIV-HCV co-infected people (Menon et al., 2010; Morar et al., 2010) .
Cyclosporin use is recommended up to 12 weeks, because of adverse effects (AE) such as hypertension and nephrotoxicity, for which a strict monitoring is needed. Moreover, a careful prescription is needed in patients assuming Protease Inhibitors, because of its raised bioavailability when co-administration happens (Morar et al., 2010) .
| Hydroxyurea
Hydroxyurea is an old drug used for the treatment of chronic myeloid leukemia and sickle cell anemia. Its mechanism of action is the inhibition of ribonucleotide-diphosphate reductase, leading to an inhibition of DNA synthesis and cell proliferation (Lee et al., 2011; Menon et al., 2010) . It is also characterized by some antiviral properties, therefore its use in PLWH has been postulated (Lee et al., 2011; Menon et al., 2010) .
However, evidences about its usefulness for the treatment of severe psoriasis are poor and the right dose has not been established (Menon et al., 2010) . Moreover, its use is burdened by serious adverse events (SAEs) such as anemia, leukopenia, thrombocytopenia, macrocytosis, and diarrhea, which are luckily reversible after discontinuation (Lee et al., 2011) .
Due to the SAEs connected to hydroxyurea, its use is limited to refractory cases and under strict monitoring by the HIV specialist (Menon et al., 2010; Morar et al., 2010) .
| Biologic treatments
This class of biologic drugs includes monoclonal antibodies and enzyme inhibitors with multiple therapeutic mechanisms, such as targeting TNFα directly or neutralizing soluble receptor antagonists (Fink et al., 2017; Rustin, 2012) . Seeing that TNFα is a pro-inflammatory cytokine, the ultimate effect of these drugs is reduction of the inflammation, but they also impair appropriate immune responses to infections (Fink et al., 2017; Rustin, 2012) . Linardaki, Katsarou, Ioannidou, Karafoulidou, & Boki, 2007; Mikhail, Weinberg, & Smith, 2008; Paparizos et al., 2012; Reddy et al., 2017; Sellam et al., 2007; Sha et al., 2002; Wallis et al., 2004) .
Data available in literature highlights that treatment responses in PLWH are comparable to those observed in HIV-negative patients affected by psoriasis (Fink et al., 2017) . Moreover, there are no negative effects on ART (Fink et al., 2017) . However, even though Cepeda et al. (2008) suggested that anti-TNFα treatments are effective and well tolerated in PLWH with a CD4+ T-lymphocyte count >200/mm 3 , there are only limited efficacy and safety data, and some authors suggest limiting the use of anti-TNFα agents to those unresponsive to standard therapeutic regimens (Bartke et al., 2004; Cepeda et al., 2008; Cobo Ibáñez et al., 2009; De Simone et al., 2016; Di Lernia et al., 2013; Gaylis, 2003; Kaur et al., 2007; Linardaki et al., 2007; Mikhail et al., 2008; Paparizos et al., 2012; Reddy et al., 2017; Sellam et al., 2007; Sha et al., 2002; Wallis et al., 2004 ).
An increased risk for infections has been observed when CD4+
T-lymphocyte count is below 50/mm 3 , especially with etanercept (Aboulafia et al., 2000; Cepeda et al., 2008) .
| Infliximab
Infliximab is a chimeric monoclonal anti-TNFα antibody used for the treatment of psoriasis and psoriatic arthritis, reported to be effective and well tolerated on cutaneous and joint symptoms. Moreover, there are currently no reports of adverse effects on CD4 T-lymphocyte count and HIV plasmatic viral load (Bartke et al., 2004; Gaylis, 2003; Sellam et al., 2007) .
| Etanercept
Etanercept is a soluble p75 TNFα receptor fusion protein, successfully used to treat several PLWH unresponsive to conventional drugs.
Studies have demonstrated etanercept efficacy and safety in PLWH, also in those burdened by comorbidities (Di Lernia et al., 2013; Kaur et al., 2007; Linardaki et al., 2007; Sha et al., 2002; Wallis et al., 2004) .
It is particularly useful in pustular psoriasis forms (Mikhail et al., 2008) .
| Ustekinumab
Ustekinumab is an IgG1k monoclonal antibody linking IL12 and IL23. Its action leads to a decreased release of pro-inflammatory cytokines such as TNFα and IL1 (Paparizos et al., 2012) . The use of ustekinumab is approved for the treatment of severe chronical psoriasis and psoriatic arthritis. It is reported to not affect negatively CD4+ T-lymphocyte count and HIV plasmatic viral load (Paparizos et al., 2012) .
| Apremilast
Apremilast is a small oral molecule acting as a selective inhibitor of phosphodiesterase 4 (PDE4). Its action causes a decreased production of TNFα (Reddy et al., 2017) . It is approved for the treatment of psoriasis and psoriatic arthritis since 2014, even though literature reporting its use in PLWH is scarce and limited to case reports (Reddy et al., 2017) . Most frequent AE are represented by gastro-intestinal disorders (diarrhea, nausea, vomiting), psychiatric disorders (depression, suicidal thoughts), weight loss (Reddy et al., 2017) .
It is reported to have a good safety profile over CD4+
T-lymphocyte count and HIV plasmatic viral load (Reddy et al., 2017) .
| Future developments
Agents acting against IL-17A, such as secukinumab, ixekizumab, and brodalumab, have been recently approved for the treatment of moderate and severe psoriasis (Silfavast-Kaiser, Paek, & Menter, 2018) .
However, there are still no evidences about their safety and effectiveness in PLWH.
More studies are needed before they can be considered for clinical practice in PLWH.
| CONCLUSIONS
A correct management of psoriasis in PLWH is necessary, because of the high risk of worsen the conditions of an already impaired immune system existing in these patients.
Topical treatments can be useful when associated to cART for mild forms, while moderate and severe forms need a more aggressive treatment of choice, often systemic, with immunosuppressive drugs.
However, knowledge about the risk connected with the use of these drugs in PLWH is often limited to case-reports and small series of cases, therefore, further studies are needed to determine if immunosuppressive drugs can be safely and effectively used in PLWH affected by psoriasis and other autoimmune disorders.
